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The helicase HAGE prevents interferon-a-induced PML
expression in ABCB5þ malignantmelanoma-initiating
cells by promoting the expression of SOCS1
MG Mathieu1,2, AK Miles1,2, M Ahmad1, ME Buczek1, AG Pockley1, RC Rees1 and T Regad*,1
The tumour suppressor PML (promyelocytic leukaemia protein) regulates several cellular pathways involving cell growth,
apoptosis, differentiation and senescence. PML also has an important role in the regulation of stem cell proliferation and
differentiation. Here, we show the involvement of the helicase HAGE in the transcriptional repression of PML expression in
ABCB5þ malignant melanoma-initiating cells (ABCB5þ MMICs), a population of cancer stem cells which are responsible for
melanoma growth, progression and resistance to drug-based therapy. HAGE prevents PML gene expression by inhibiting the
activation of the JAK–STAT (janus kinase–signal transducers and activators of transcription) pathway in a mechanism which
implicates the suppressor of cytokine signalling 1 (SOCS1). Knockdown of HAGE led to a significant decrease in SOCS1 protein
expression, activation of the JAK–STAT signalling cascade and a consequent increase of PML expression. To confirm that the
reduction in SOCS1 expression was dependent on the HAGE helicase activity, we showed that SOCS1, effectively silenced by
small interfering RNA, could be rescued by re-introduction of HAGE into cells lacking HAGE. Furthermore, we provide a
mechanism by which HAGE promotes SOCS1 mRNA unwinding and protein expression in vitro. Finally, using a stem cell
proliferation assay and tumour xenotransplantation assay in non-obese diabetic/severe combined immunodeficiency mice,
we show that HAGE promotes MMICs-dependent tumour initiation and tumour growth by preventing the anti-proliferative effects
of interferon-a (IFNa). Our results suggest that the helicase HAGE has a key role in the resistance of ABCB5þ MMICs to IFNa
treatment and that cancer therapies targeting HAGE may have broad implications for the treatment of malignant melanoma.
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Malignant melanoma-initiating cells (MMICs) are a population
of cancer cells that possess the stem cell properties of self-
renewal and differentiation.1 This population of cells express
the ATP-binding cassette member 5 (ABCB5), a protein that
renders malignant melanoma drug-resistant and refractory to
therapy. ABCB5þ MMICs also express HAGE (DDX43), a
DEAD-Box RNA helicase expressed specifically by tumour
cells, that has been shown to have a key role in promoting
the proliferation of ABCB5þ MMICs and their survival by
enhancing the expression of the small GTPase NRAS.2 As a
consequence, this population is thought to be responsible for a
highly aggressive type of cancer with a poor prognostic
outcome.3,4 Besides drug-based therapy, interferon-a (IFNa)
has also been used for the treatment of patients with malignant
melanoma and has been shown to result in a modest
improvement of relapse-free survival and overall survival.5–7
The mechanisms underlying resistance to IFNa treatment and
the involvement of MMICs in this process are unknown.
IFNa signals through the JAK–STAT (janus kinase–signal
transducers and activators of transcription) pathway and
results in the induction of several genes. This endows IFNa
with multiple effects in a variety of malignancies that range
from antiangiogenic effects to potent immunoregulatory,
differentiation-inducing, pro-apoptotic and anti-proliferative
properties.8,9 The gene encoding promyelocytic leukaemia
protein (PML) is a well-known downstream target of IFNs
signalling and its induction by IFNs results in a significant
increase in the expression of PML and the number of PML
nuclear bodies (PML-NBs).10–12 PML, a member of the Ring-
B Box-Coiled Coil family, is a tumour suppressor which was
originally identified at the breakpoint of the t (15;17)
translocation found in acute promyelocytic leukaemia
(APL).13–15 It is at the heart of many cellular pathways such
as cell growth, differentiation, DNA damage, senescence,
apoptosis and anti-viral responsiveness.16–18 PML functions
by interacting and recruiting different factors that compose
these cellular processes into subnuclear structures known as
PML-NBs, of which it is the essential component.18 Although
the role of PML in IFNs-mediated antiviral responses has
been well studied, little is known about its role in the
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anti-tumour properties of IFNs.16,19 On the basis of this
background, we hypothesised that the helicase HAGE
(DDX43) may endow MMICs with a resistance to the anti-
tumour effects of IFN-induced PML. Here, we reveal a
previously unknown role of HAGE, namely that it ensures
the survival of MMICs in response to the anti-proliferative and
pro-apoptotic effects of IFNa. Using a stem cell proliferation
assay and tumour xenotransplantation assay in non-obese
diabetic/severe combined immunodeficiency (NOD/SCID)
mice, we show that HAGE promotes tumour initiation and
MMIC-dependent growth by preventing the IFNa-induced
inhibition. HAGE expression in malignant melanoma cells
prevents the activation of the JAK–STAT signalling pathway
which is involved in the induction of PML transcription.
Knockdown of HAGE in ABCB5þ MMICs results in increased
PML expression at the RNA and protein levels. This event is
favoured through an increase in expression of the suppressor
of cytokine signalling SOCS1 protein, a known positive
regulator of ubiquitination and degradation of JAK proteins.20
HAGE knockdown in melanoma cell lines expressing ABCB5
decreases SOCS1 protein expression and this is reversed by
re-introducing HAGE in these cells. An in vitro unwinding
assay provides a mechanistic insight by demonstrating the
capacity of the helicase HAGE to unwind SOCS1 RNA
complexes and thereby promote the expression of SOCS1
protein. Collectively, these findings support the model by
which HAGE promotes the initiation of tumours by ABCB5þ
MMICs and their resistance to the anti-proliferative effects of
IFNa by inactivating the JAK–STAT pathway which is
necessary for PML expression via a mechanism which
involves the SOCS1.
Results
Decreased PML expression in HAGEþ ABCB5þ
MMICs. The loss of PML expression has been previously
reported in several solid tumours from different tissue
origins.21 To investigate the expression status of PML in
HAGEþ and ABCB5þ MMICs, we performed immunostaining
on a malignant melanoma tissue microarray (TMA) using
antibodies against PML, HAGE and ABCB5. PML expression
was significantly decreased in HAGEþ and ABCB5þ
tumour cells when compared with the control (normal skin).
As a consequence, this decrease correlated with the
absence of PML-NBs of which, PML is the essential
component. PML has been shown to promote the hypo-
phosphorylation of the retinoblastoma protein (Rb), which
regulates the cell cycle progression at the G1–S phase by
interacting and sequestering the transcription factor E2F.22
Immunostaining on a malignant melanoma TMA using an
antibody against the phosphorylated forms of Rb showed an
increased expression of phosphorylated Rb in malignant
melanoma when compared with the normal skin control
(Figure 1). Furthermore, PML expression was found in
melanocytes of normal skin and in HAGEþ ABCB5þ
melanoma cells as shown using an antibody against
Tyrosinase, a specific marker of melanin-producing cells.
Interestingly, PML was expressed in tissues surrounding
ABCB5- and HAGE-expressing cells within the tumours
(Figure 1 and Supplementary Figure 1). Similar results were
obtained using malignant melanoma cell lines FM82 and
FM55, which co-express HAGE and ABCB5.2 The perma-
nent knockdown of HAGE in these cell lines using small
hairpin RNAs (FM82 shRNA 1 and 2, FM55 shRNA 1 and 2)
increased PML expression (Figure 2a). The molecular weight
of the PML protein (B90KDa) observed by immunoblotting
(IB) suggests that the dominant isoform expressed in these
cell lines may corresponds to PML isoforms II, III or both.
To further investigate this, we have tested by IB two additional
antibodies on whole cell extracts from FM82 control, FM82
shRNA and another melanoma cell line FM6 (Supplementary
Figures 2B and C). The first antibody recognises the PML
epitope, which maps to a region between 375 and 425 and
therefore should recognises all PML isoforms with the
exception of isoforms VI and VII. The second antibody
recognises the PML epitope, which maps to a region
between 575 and 625 and should only recognise PML I
and PML IV. The immunoblot using the first antibody showed
predominant expression of a band at B90 kDa, however,
the immunoblot with the second antibody showed
weak expression of bands at B80 kDa andB100 kDa
(Supplementary Figures 2B and C). From these results, we
concluded that the predominant band at B90 kDa may
represent PML isoforms II or III or both. The decreased
expression of PML protein in the presence of HAGE might
result from a decrease in PML gene expression. We
investigated this possibility by performing a semi-quantitative
real-time PCR on mRNAs isolated from FM82 and FM55
controls and FM82 and FM55 shRNAs cell lines. We found
that HAGE knockdown resulted in increased PML gene
expression when compared with controls (Figure 2b). These
results suggest that HAGE negatively regulates the basal
expression of PML gene in HAGEþ ABCB5þ MMICs.
HAGE prevents IFN-induced PML expression. The binding
of type I IFNs to the IFNa receptor (IFNAR) triggers the
activation of Jak proteins (Jak1 and Tyk2) which become
auto-phosphorylated and activate members of the STAT
family through tyrosine phosphorylation. Activated STATs
form dimers, translocate to the nucleus, bind to specific
response elements in promoters of target genes and
transcriptionally activate these genes9 (Figure 2c). The
PML gene promoter possesses an IFN-stimulated response
element, which is inducible by IFN type I (Figure 2c). To
investigate the mechanism by which HAGE regulates PML
gene expression, FM82 and FM55 controls and FM82 and
Figure 1 Expression of PML in HAGE-positive and ABCB5-positive malignant melanoma. Top panel: representative image of immunohistochemistry with antibodies to
PML (green) or ABCB5 (green) or Tyrosinase (red) or HAGE (red) or phospho-Rb (green) on normal skin sections. The arrows indicate PML-NBs in Tyrosine-positive cells.
Lower panel: representative image of immunohistochemistry with antibody to PML (green or red), ABCB5 (green), Tyrosinase (red), HAGE (red) or phospho-Rb (green) in
malignant melanoma tissue sections. The negative controls used were an IgG isotype from mouse and rabbit. The blue staining (DAPI) corresponds to the nucleus. Scale bars
represent 100 mm (20 ), 50mm (40 ), 20mM (40 )
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FM55 shRNAs were treated with IFNa. PML protein expres-
sion upon IFNa treatment was significantly increased in
HAGE knockdown cell lines when compared with FM82 and
FM55 control (Figures 2d and e). This result suggests that
HAGE prevents IFNa-mediated PML gene expression.
Analysis of the JAK–STAT pathway in FM82 and FM55
controls and FM82 and FM55 shRNAs following IFNa
treatment showed a decrease in Jak1, Tyk2, STAT1 and
STAT2 phosphorylation in the presence of HAGE (Figures 2f,
g, i and j). This downregulation of the JAK–STAT pathway
might be due to a decrease in IFNAR expression on the
surface of FM82 and FM55 control cells, thereby resulting
in a reduced ligand binding. IB with a specific antibody to
IFNAR and using lysates from FM82 and FM55 controls and
FM82 and FM55 shRNAs showed no significant difference in
IFNAR expression in the presence of HAGE and when HAGE
is knocked down (Figure 2l). Finally, IB using antibodies to
total Jak1, Tyk2, Stat1 and Stat2 showed no difference in
their expression in FM82 and FM55 controls and FM82 and
FM55 shRNAs (Figures 2h and k). As the phosphorylation of
STAT1 and STAT2, and the dimerisation, nuclear transloca-
tion and activation of target genes are dependent on Jak1
and Tyk2 auto-phosphorylation (p-Jak1 and p-Tyk2). These
results suggest that HAGE prevents IFNa-mediated PML
gene expression via a negative regulation of Jak1 and Tyk2
phosphorylation.
HAGE promotes the expression of SOCS1. The SOCS1
belongs to the SOCS family of negative regulators of the
JAK–STAT pathway. SOCS proteins can directly bind to the
phosphorylated forms of JAKs via their central domain SH2
and the C-terminal SOCS box region. This binding triggers
the ubiquitination and degradation of JAKs through the
formation of an E3 ubiquitin ligase complex comprising
Cullin2 and the elongin B/C20 (Figure 3a). To investigate the
potential involvement of SOCS1 in the HAGE-mediated
downregulation of p-Jak1 and p-Tyk2, we performed an
immunostaining with antibodies against HAGE and SOCS1
on FM82 control and FM82 shRNAs cell lines. SOCS1 was
co-expressed together with HAGE in FM82 controls and its
expression decreased when HAGE was knocked down
(FM82 shRNAs) (Figure 3b). These results were confirmed
by IB using cell extracts from FM82 and FM55 controls and
FM82 and FM55 shRNAs (Figure 3b). Interestingly, SOCS3,
another member of the SOCS family of proteins was also
downregulated in FM82 and FM55 shRNAs (Supplementary
Figure 2A). However, we were not able to detect SOCS2
another member of this family by IB using a previously
described SOCS2 specific antibody (data not shown).23
Furthermore, SOCS1 expression was increased in HAGE-
positive malignant melanoma tissue, thereby confirming the
in vitro observations above (Figure 3c). To determine the
functional relationship between HAGE and SOCS1, we used
knockdown experiments using specific small interfering RNAs
(siRNAs) for SOCS1 mRNA in FM82 and FM55 controls cell
lines which naturally express HAGE. SOCS1 knockdown
increased the expression of p-Jak1, p-Tyk2 and PML protein
and suggested that SOCS1 has a role in HAGE-mediated
downregulation of JAK–STAT–PML pathway (Figure 3d).
RNA helicases of the DEAD-box family unwind RNA
duplexes by local strand separation in an ATP-dependent
fashion. As a result, RNA helicases are involved in specific
processes such as ribosome biogenesis, pre-mRNA splicing
and translation.24–26 HAGE may enhance SOCS1 translation
and promote its expression by unwinding and stabilising
SOCS1 mRNA. To investigate if HAGE promotes the
expression of SOCS1 protein, we knocked down SOCS1
mRNA in FM82 control and in FM82 shRNA1 cell lines.
SOCS1 protein level was significantly decreased in FM82
shRNA when compared with FM82 control (Figure 3e).
Furthermore, SOCS1 protein expression was significantly
restored when HAGE was ectopically expressed in FM82
shRNA1 transfected with a HAGE-expressing plasmid
(Figure 3e). The decrease of SOCS1 expression was not
due to a decrease of its mRNA expression upon HAGE
knockdown as no significant changes in SOCS1 mRNA
expression were observed by semi-quantitative real-time
PCR on RNAs isolated from FM82 and FM55 controls and
FM82 and FM55 shRNAs cell lines (Figure 3f). HAGE may
promote SOCS1 protein expression through its unwinding
activity towards SOCS1 RNA. To determine if HAGE induces
the unwinding of SOCS1 RNA, we performed an in vitro RNA
unwinding assay in the absence or presence of different
concentrations of recombinant HAGE protein and SOCS1
RNA duplexes. Remarkably, HAGE was able to unwind
SOCS1 RNA duplexes in a dose-dependent fashion
(Figure 3g). Finally, ectopic expression of HAGE promoted
the translation of SOCS1 as shown by IB and using a
metabolic labelling assay of nascent protein synthesis
(Figure 3h).23,27 Taken together, these results suggest that
Figure 2 Expression of PML in malignant melanoma cell lines and JAK–STAT pathway analysis in IFNa treated and untreated FM82 and FM55 control and FM82 and
FM55 shRNA malignant melanoma cell lines. (a) Left panel: IF with antibodies to PML (green), ABCB5 (green) and HAGE (red) on FM82 control and FM82 shRNA1 and 2
(HAGE knocked down). Right panel: IB with antibodies to HAGE, ABCB5, PML and actin (loading control) using whole lysates from FM82 and FM55 control and FM82 and
FM55 shRNA1 and 2. (b) Semi-quantitative real-time PCR of PML mRNAs isolated from FM82 control and FM82 shRNA1. Mann–Whitney U-test: ***P¼o0.001.
(c) Schematic representation of JAK–STAT signalling pathway upon induction by IFN type I. (d and e) IB with antibodies to PML, HAGE and actin using whole extracts from
IFNa treated (16 h) and untreated FM82 and FM55 control and FM82 and FM55 shRNA1 and 2. Quantification of PML protein expression in plus and minus IFNa-treated cells.
(f) IB with antibodies to the phosphorylated forms of Jak1, Tyk2, STAT1 and STAT2 using whole cell extracts from IFNa treated (0.25 h) and untreated FM82 control and FM82
shRNA1 and 2. (g) Quantification of the phosphorylated forms of Jak1, Tyk2, STAT1 and STAT2 using whole cell extracts from IFNa treated (0.25 h) and untreated FM82
control and FM82 shRNA1 and 2. (h) IB with antibodies to total Jak1, Tyk2, STAT1 and STAT2 using whole extracts from FM82 control and FM82 shRNA1 and 2.
(i) Values expressed in Arbitrary Units (AU) using Aida Image Analyser (v.3.52) IB with antibodies to the phosphorylated forms of Jak1, Tyk2, STAT1 and STAT2 using whole
cell extracts from IFNa treated (0.25 h) and untreated FM55 control and FM55 shRNA1 and 2. (j) Quantification of the phosphorylated forms of Jak1, Tyk2, STAT1 and STAT2
using whole cell extracts from IFNa treated (0.25 h) and untreated FM55 control and FM55 shRNA1 and 2. (k) IB with antibodies to total Jak1, Tyk2, STAT1 and STAT2 using
whole extracts from FM55 control and FM55 shRNA1 and 2. (l) IB with antibody to IFN a/b receptor (IFN receptor type I) and actin using whole extracts from untreated FM82
and FM55 control and FM82 and FM55 shRNA1 and 2
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HAGE enhances the expression of SOCS1 protein expres-
sion by promoting SOCS1 RNA unwinding.
SOCS1 promotes p-Jak1 and p-Tyk2 ubiquitination.
SOCS1 has been shown to inhibit the JAK–STAT pathway
by interacting with the phosphorylated forms of Janus protein
kinases.28,29 To investigate the potential interaction of
SOCS1 with p-Jak1 and p-Tyk2, we performed an immuno-
precipitation (IP) of cell extracts from FM82 control using
SOCS1 antibody. IB of SOCS1 immunoprecipitates with
antibodies against SOCS1, p-Jak1 and p-Tyk2 revealed the
presence of SOCS1, p-Jak1 and p-Tyk2 in SOCS1 immuno-
complexes (Figure 4a). SOCS1 interactions with p-Jak1 and
p-Tyk2 may result in their ubiquitination and therefore
their degradation by the ubiquitin proteasome system
(Figure 4a). To investigate this possibility, we performed
IPs of cell extracts from FM82 control and FM82 shRNA
using antibodies against p-Jak1 and p-Tyk2. IB using
antibodies against p-Jak1, p-Tyk2 and ubiquitin revealed
the presence of p-Jak1 and p-Tyk2 in p-Jak1 and p-Tyk2
immunoprecipitates, respectively. Furthermore, p-Jak1 and
p-Tyk2 were highly ubiquitinated in the FM82 control
immunoprecipitates when compared with FM82 shRNA
immunoprecipitates (Figures 4b and c). Finally, the rescue
of HAGE or SOCS1 expression by ectopic expression in
FM82 shRNA1 promoted the ubiquitination status of p-Jak1
(Figure 4d). These results demonstrate that SOCS1 interac-
tion with p-Jak1 and p-Tyk2 promotes their ubiquitination and
this increases in the presence of HAGE.
HAGE provide ABCB5þMMICs resistance to the
anti-proliferative effect IFNa in vivo. We have previously
shown that HAGE is expressed by ABCB5þ MMICs. These
cells possess the capacity of self-renewal and differentiation
into ABCB5þ or ABCB5 cells.2 To investigate if HAGE
provides resistance to the anti-proliferative effect of IFNa
treatment mediated at least through PML, we performed a
self-renewal assay using FM82 control and FM82 shRNA
cell lines. These melanoma spheres were stained using
antibodies against HAGE, ABCB5, SOCS1 and PML.
Figure 3 HAGE enhances SOCS1 RNA unwinding and protein expression. (a) Schematic representation of the mechanism of action of SOCS1. (b) Left panel: IF with
antibodies to SOCS1 (green) and HAGE (red) on FM82 control and FM82 shRNA1 and 2 (HAGE knocked down). Right panel: IB with antibodies to HAGE, SOCS1 and actin
(loading control) using whole lysates from FM82 and FM55 control and FM82 and FM55 shRNA1 and 2. Scale bar 50mm. (c) Representative image of immunohistochemistry
with antibodies to SOCS1 (green) and HAGE (red) on normal skin and malignant melanoma sections. Scale bar 100mm. (d) IB with antibodies to HAGE, SOCS1, p-Jak1,
p-Tyk2, PML and actin using whole cell extracts from FM82 and FM55 control and FM82 and FM55 shRNA1 and 2 transfected with siRNA control and siRNA for SOCS1
mRNA. (e) Transient silencing of SOCS1 in HAGE stable knockdown and control FM82 cells followed by rescue of HAGE expression using a HAGE cDNA expression vector.
Actin was measured as a loading control. (f) Semi-quantitative real-time PCR of SOCS1 mRNAs isolated from FM82 control and FM82 shRNA1. (g) Unwinding of biotinylated
SOCS1 N-terminal complimentary RNA sequence-SOCS1 RNA duplexes in the presence of increasing HAGE protein concentrations (lane 1: 0mg, lane 2: 0.6mg, lane 3:
1.2mg). Biotinylated SOCS1 N-terminal complimentary RNA sequence was used as a loading control in lane 4. (h) IP with antibody to SOCS1 of biotin alkyle metabolically
labelled (30, 60 and 120 min) and unlabelled SOCS1 proteins followed by IB with streptavidin antibody from FM82 control whole cell extracts transfected with SOCS1cDNA
and with or without transfected HAGE cDNA
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Interestingly, SOCS1 was highly expressed in FM82 control
when compared with FM82 shRNAs. In contrast, PML
expression was higher in FM82 shRNAs when compared
with FM82 control (Figures 5a, b and c). Furthermore,
melanoma spheres generated from FM82 stably expressing
PMLII gave rise to smaller spheres when compared with
FM82 stably expressing the empty vector (Figures 5d and e).
The ectopic expression of HAGE or SOCS1 in FM82 stably
expressing PMLII did not affect the anti-proliferative effect of
PMLII on the spheres growth (Figure 5e). In addition, PML
knockdown by lentiviral expression of PML shRNAs in
FM82 shRNA resulted in significantly bigger sized spheres
when compared with spheres generated from FM82 shRNA
infected with control lentiviruses (Figures 5f and g). Finally,
IFNa treatment of growing FM82 and FM55 control and
FM82 and FM55 shRNA melanoma spheres resulted in
significantly smaller FM82 and FM55 shRNA spheres
when compared with the FM82 and FM55 control spheres
Figure 4 SOCS1 induces ubiquitination of p-Jak1 and p-Tyk2 in FM82 control malignant melanoma cell lines. (a) IP with antibody to SOCS1 or rabbit IgG followed by IB
with antibodies to SOCS1, p-Jak1 and p-Tyk2 from FM82 control whole cell extracts. (b and c) IP with antibody to p-Jak1 or p-Tyk2 and corresponding IgG (rabbit or goat,
respectively) followed by IB with antibodies to p-Jak1 or p-Tyk2 and ubiquitin from FM82 control and FM82 shRNA1 whole cell extracts. (d) IP with antibody to p-Jak1 followed
by whole cell extracts IB with an antibody to ubiquitin from FM82 shRNA1 transfected with HAGE cDNA or SOCS1 cDNA. The protein expression of HAGE and SOCS1 was
determined by IB with the corresponding antibodies
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(Figures 6a, b and c). Similar results were observed with
tumours derived from FM82 (control) and FM82 shRNA cell
lines that had been xenotransplanted into NOD/SCID mice
and treated with IFNa (Figures 6d and e). Immunostaining of
sections from these tumours using PML antibody revealed an
increased expression of PML in FM82 shRNA tumours
treated with IFNa when compared with FM82 control, FM82
control treated with IFNa and IFNa untreated FM82 shRNA-
derived tumours (Figure 6f). PML increased expression in
IFNa-treated FM82 shRNA-derived tumours correlated with
Figure 5 HAGE counteracts the anti-proliferative effect of IFNa in ABCB5þ MMICs. (a, b and c) IF with antibodies to HAGE (red), ABCB5 (green), SOCS1 (green) and
PML (green) on FM82 control, FM82 shRNA1 and 2 melanoma spheres. (d) IF and IB with an antibody to PML (or IgG) on FM82 cell lines and corresponding melanoma
spheres stably-expressing PML or the empty vector. (e) FM82 empty vector and stably expressing PML spheres formation in the presence or absence of cDNA transfected
HAGE or SOCS1. ANOVA: ***P¼o0.0001. Scale bar 100mm (for spheres) and 20mm (for cells). (f) IF and IB with an antibody to PML on FM82 shRNA/PMLshRNA CTL
and FM82shRNA/PMLshRNA 1 and 2. (g) Spheres formation assay from FM82shRNA/PMLshRNA CTL and FM82shRNA/PML shRNA 1 and 2. ANOVA: ***P¼o0.0001
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Figure 6 HAGE counteracts the anti-proliferative effect of IFNa in vivo. (a, b and c) FM82 and FM55 controls and FM82 and FM55 shRNA 1 and 2 melanoma sphere
formation in the presence or absence of IFNa. Student t-test: **P¼o0.01. (d) Summary of the in vivo experimental procedure. (e) Measurement of tumour growth in mice
injected with either FM82 control cells or FM82 shRNA1 cells and treated or untreated with IFNa ANOVA: **P¼o0.0028; Mann–Whitney U-test: *P¼o0.0108 (when
comparing FM82 control þ PBS and FM82 shRNA þ PBS; Mann–Whitney U-test: **P¼o0.0079 (when comparing FM82 control þ IFNa and FM82 shRNA þ IFNa
treated). (f) Immunohistochemistry/fluorescence staining with antibodies to HAGE (red), ABCB5 (green), SOCS1 (green) and on sections from FM82 control and FM82
shRNA1 NOD/SCID xenotransplanted tumours and treated or untreated with IFNa. Scale bar 100 mm
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an increased apoptosis and a decreased cellularity in these
tumours when compared with FM82 control, FM82 control
treated with IFNa and IFNa-untreated FM82 shRNA-derived
tumours (Figures 7a and b). Taken together, these results
suggest that HAGE expression in ABCB5þ MMICs provides
resistance to IFN alpha-PML mediated anti-proliferative and
Figure 7 IFNa treatment of HAGE knocked down NOD/Scid xenotransplanted tumours results in a decreased cellularity and increased apoptosis. (a) Hematoxylin and
eosin stain on sections from FM82 control and FM82 shRNA1 NOD/SCID xenotransplanted tumours and treated or untreated with IFNa. ANOVA: ***P¼o0.0001 (b)
Immunohistochemistry/IF staining with antibody against the apoptotic marker cleaved caspase 3 on sections from FM82 control and FM82 shRNA1 NOD/SCID
xenotransplanted tumours and treated or untreated with IFNa. ANOVA: ***P¼o0.0001. (c) Proposed schematic representation of the mechanism by which the helicase
HAGE inactivate the anti-proliferative effect of IFNa in ABCB5þ MMICs
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pro-apoptotic effects by promoting the expression of SOCS1
and the inhibition of PML expression through the inactivation
of JAK–STAT pathway (Figure 7c).
Discussion
Chemotherapy and adjuvant IFNa therapy have been used to
prevent recurrence of disease in patients with malignant
melanoma. Despite important advances, the fact that many
patients develop resistance to these therapies highlights the
need to identify and further dissect the cellular and molecular
mechanisms that are involved in this resistance.5MMICs have
been shown to offer such resistance to chemotherapy via their
expression of ABCB5. This allows these populations to initiate
and perpetuate their malignancy.1 In this regard, the
mechanisms implicating ABCB5þ MMICs in chemo-resis-
tance have been well studied.3,4,30 However, it is not known if
these populations of melanoma cancer stem cells are
implicated in the resistance to IFNa therapy. This study
focused on investigating thosemechanisms with an emphasis
on molecules that are involved in the JAK–STAT signalling
cascade, a pathway which is activated by IFNa.9 Indeed, we
show here that the helicase HAGE provide MMICs with
resistance to the anti-proliferative effects of IFNa by enhan-
cing the expression of SOCS1, a negative regulator of JAK–
STAT pathway.20,31 We have previously shown that HAGE
promotes the proliferation and survival of MMICs by promot-
ing the unwinding and the translation of NRAS mRNA.2
Consistently, a similar mechanism is described here, where
we show that HAGE unwinds SOCS1 mRNAs/siRNA
duplexes and may therefore promote SOCS1 translation in
tumour cells. SOCS1, a ubiquitin E3 ligase, has been shown
to bind the phosphorylated forms of JAKs proteins, trigger
their ubiquitination and prime them for protein degrada-
tion.28,29,31 We show that HAGE knockdown results in a
decreased ubiquitination of p-Jak1 and p-Tyk2, which further
demonstrates a functional link between HAGE and SOCS1.
Furthermore, SOCS1 was found to be highly expressed in
HAGE-expressing tumour cells highlighting the importance of
this molecule in melanoma progression. SOCS1 has also
been shown to have an important role in melanoma progres-
sion and in the downregulation of biological responses by
endogenous and/or therapeutically administered cyto-
kines.32,33 The tumour suppressor PML has an important role
in many cellular processes such as cell growth, apoptosis and
differentiation. PML exerts its functions by interacting and
recruiting different factors into subnuclear structures known
as PML-NBs.17,18 PML localisation is not restricted to PML-
NBs and it is observed to be present in other cellular
compartments such as the nucleoplasm, the nucleolus, the
nuclear envelope and the cytoplasm.34 The PML gene
encodes a variety of isoforms, which are found in all human
cell types, with isoform I/II having the highest levels of
expression.35 Expression of PML and its isoforms can be
induced at the transcriptional level by the JAK–STAT pathway
in response to IFN. Interestingly, PML II, PMLIII or both seem
to be predominantly expressed in malignant melanoma cell
lines and their level of expression increases following IFNa
treatment. Although the localisation of this isoform is mostly
nuclear, a cytoplasmic expression can also be observed.
As HAGE prevents the activation of the JAK–STAT pathway
in ABCB5þ MMICs, it appears that PML mRNA expression
appears to be affected and this leads to the observed
decrease in PML protein expression. This is probably the
case, as PML expression upon IFNa treatment was also
affected by HAGE expression. Moreover, several studies
have reported a role for PML in the regulation of stem cell
proliferation and differentiation22,36 and this effect involving
HAGEmight be one of the mechanisms by which cancer stem
cells avoid the anti-proliferative and pro-apoptotic responses
mediated by PML. Interestingly, PML expression is found in
the cells surrounding HAGEþ cells, which suggest that
HAGE targets specifically PML to prevent its anti-proliferative
and pro-apoptotic functions. Furthermore, FM82 HAGE
shRNA tumours treated with IFNa have an increased level
of PML expression (and PML-NBs), higher levels of apoptosis
and lower cellularity. Finally, PML knock down in FM82 HAGE
shRNA resulted in increased size of spheres which pointed
out to the specific targeting of PML by HAGE.
Collectively, these findings provide evidence for a pre-
viously unknown role of HAGE in ABCB5þ MMIC-dependent
resistance to PML-mediated anti-proliferative response of
IFNa. We clearly demonstrate that HAGE prevents the
activation of JAK–STAT pathway responsible for the induction
of the expression of the tumour suppressor PML. Finally, as
HAGE is expressed only by tumour cells, these results
suggest that cancer therapies targeting HAGE helicase may
have broad applications for treating ABCB5þ malignant
melanoma and for preventing resistance to IFNa treatment.
Materials and Methods
Cell lines and growth conditions. The human melanoma cell lines,
FM82, FM55 and FM6, were a kind gift from Professor D. Schadendorff of
the Deutsches Krebsforschungszentrum (Heidelberg, Germany). All cells were
cultured as previously described2 in RPMI 1640 media (Lonza, Basel, Switzerland)
supplemented with 10% (v/v) fetal calf serum and 1% (w/v) L-glutamine (Lonza).
Cells were incubated at 37 1C in 5% (v/v) CO2 and 100% humidity. IFNa2a
(IMR-236, Imgenex, San Diego, CA, USA) was used at a concentration of 1000 U/ml.
Stable and transient transfection of cell lines. A stable knockdown
cell line was created using shRNA-bearing plasmids specific for HAGE (Sure
Silencing shRNA Plasmid for Human DDX43, SABiosciences, Crawley, UK). FM82
and FM55 cells were seeded at 5 104 cells/well into a 24-well plate and grown
overnight. About 1.2mg of SureSilencing shRNA were transfected into cells using
Lipofectamine 2000 (Invitrogen, Paisley, UK), as described by the manufacturer.
Forty-eight hours later, the cells were seeded into a 96-well plate and grown in
media treated with 500mg/ml G418 antibiotic to allow selection of plasmid-
transfected cells. HAGE expression status was monitored using semi-quantitative
real-time PCR, western-blotting and immunofluorescence (IF). The transient
knockdown of SOCS1 was carried out using an SOCS1-specific siRNA molecule
(Eurogentec, Southampton, UK; sense: 50-CGACAAUGCAGUCUCCACAdTdT-30;
anti-sense: 50-UGUGGAGACUGCAUUGUCGdTdT-30) and Interferin transfection
reagent (Polyplus, Illkirch, France) following the manufacturer’s recommendations.
FM82 empty vector (transfected with pcDNA3.1) and FM82 PMLII cell lines
(transfected with pcDNA3.1-PMLII, a kind gift from Dr Mounira Chelbi-Alix,
University of PARIS 5) were generated using the same procedure as above.
HAGE or SOCS1 ectopic expression were carried out using pCMV6-DLX5-HAGE
(SC126051, OriGene, Rockville, MD, USA) and pCMV6-XL4-SOCS1 (SC111081,
Origene). Transfection was performed using Lipofectamine 2000 protocol and
12mg of the vector was used to transfect a T25 flask, as described by the
manufacturer. Cells were harvested for protein extraction 48 h after transfection.
PML lentiviral plasmids shRNA control and PML shRNA1 and 2 were purcha-
sed from Sigma (St. Louis, MO, USA) (TRCN0000003866, TRCN0000003869,
SHC001). The lentiviral packaging mix was also purchased from Sigma (SHP001).
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The lentiviral particules used to infect FM82shRNA were produced corresponding
to the manufacturer recommendations.
Antibodies. For this study, we used monoclonal antibodies to HAGE (1 : 250
for IB; 1 : 50 IF, SAB1400618, Sigma), ABCB5 (1 : 500 for IB; 1 : 100 for IF,
HPA026975, Sigma), PML (1 : 500 for IF, sc-5621), PML (1 : 250 for IF; 1 : 250 for
IB, sc-966, Santa Cruz Biotechnology, Montgomery, TX, USA), PML (1 : 1000 for
WB, A310-390A PML Antibody AbVantage Pack, Bethyl Laboratories, Dallas, TX,
USA), b-actin (1 : 250 for IB, sc-130657, Santa Cruz Biotechnology), SOCS1
(1 : 300 for IB, 3950, Cell Signaling Technology, Danvers, MA, USA), SOCS1
(1 : 100 for IP, 1 : 200 for IB; 1 : 100 for IF, sc-9021, Santa Cruz Biotechnology),
Ubiquitin (1 : 300 for IB, 3933, Cell Signaling Technology), Phospho-Jak1 (1 : 300
for IB, 3331, Cell Signaling Technology), Phospho-Jak1 (1 : 100 for IP; 1 : 200 for
IB, sc-101716, Santa Cruz Biotechnology), Phospho-Stat1 (1 : 300 for IB, 9171,
Cell Signaling Technology), Phospho-Stat1 (1 : 300 for IB, 9171, Cell Signaling
Technology), Phospho-Stat2 (1 : 500 for IB, 07-224, Millipore, Billerica, MA, USA),
Phospho-Tyk2 (1 : 200 for IB; 1 : 100 for IP, sc-11763, Santa Cruz Biotechnology),
IFN a/b R (1:200 for IB, sc-7391, Santa Cruz Biotechnology), Tyrosinase (1 : 200
for IF; ab112231, Abcam, Cambridge, UK), SOCS3 (1 : 200 for IB; sc-51699,
Santa Cruz Biotechnology), SOCS2 (1 : 200 for IB; sc-9022, Santa Cruz
Biotechnology), Cleaved caspase 3 (1 : 200 for IF, 9661; Cell Signaling
Technology) and Phospho-Rb (1 : 200 for IF, 9308; Cell Signaling Technology).
Immunohistochemistry and IF. Paraffin-embedded human melanoma
TMAs were purchased from US Biomax (Rockville, MD, USA). The sections were
de-waxed, re-hydrated in graded alcohols, rinsed in ddH2O and antigen retrieval
was performed for 10 min (0.01 M citrate phosphate buffer at pH 6.0) in a
microwave at 1000 W. The tumours excised from NOD/SCID mice were
embedded in OCT media, fixed in 2-methyl-butane (Sigma) that had been
super-cooled in liquid N2 and sectioned using a CM1900 cryostat (Leica, Wetzlar,
Germany). Melanoma cells were fixed in 4% (w/v) paraformaldehyde and then
treated as follows: the sections or cancer cells were washed three times in 1X
phosphate-buffered saline (PBS) for 10 min each, blocked and permeabilised in
10% (w/v) bovine serum albumin in 0.1% (v/v) PBS-Tween, incubated overnight
with primary antibody (in blocking solution), washed three times for 10 min each
with 1X PBS, incubated for one hour with secondary antibody (in blocking solution)
and washed three times with 1X PBS. Sections and melanoma cells were
counterstained and mounted with DAPI fluorescent medium (Vector Laboratories,
Peterborough, UK) for IF microscopy.
Genetic analysis. FM82 and FM55 control and FM82 and FM55 shRNAs
cells were grown to 80% confluence as described above. Total RNA was extracted
from cells using RNA-STAT 60 reagent (AMS Biotechnology, Abingdon, UK) as
described by the manufacturer. Extracted RNAs were quantified using a Nanodrop
spectrophotometer (Thermo Scientific, Loughborough, UK). Moloney murine
leukemia virus reverse transcriptase (Promega, Madison, WI, USA), oligo-dT
primers (Promega) and 2 mg of total RNA were subsequently used for cDNA
synthesis following the manufacturer’s protocol. Semi-quantitative real-time PCR
was then carried out using primers (all MWG Eurofins, Ebersberg, Germany)
specific for PML (forward: 50-GGAGCAGGATAGTGCCTTTG-30; reverse: 50-C
TGGCCATCTCCTCGTAGTC-30, and SOCS1 (forward: 50-CGACAATG
CAGTCTCCACAG-30; reverse 50-GAGGAGGAGGAAGAGGAGGA-30) and the
housekeeping genes TBP1 (forward: 50-TGCACAGGAGCCAAGAGTGAA-30;
reverse: 50- CACATCACAGCTCCCCACCA-30) and HPRT1 (forward: 50-TGAC
ACTGGCAAAACAATGCA-30; reverse: 50-GGTCCTTTTCACCAGCAAGCT-30)
using a Rotor-Gene 6000 real-time PCR cycler (Qiagen, Venlo, The Netherlands).
Forty cycles were performed and melt curves were ratified following each analysis.
Expression of the genes of interest was normalised using averaged results for the
housekeeping genes and 2dCT calculations were performed.
IB, IP and protein metabolic labelling. For IB, cancer cells were
collected, washed with 1X PBS, lysed in 1X solution containing 50 mM Tris-HCl
(pH 6.8), 100 mM dithiothreitol, 2% (w/v) SDS, 0.1% (w/v) bromophenol blue and
10% (v/v) glycerol, and loaded on Tris/glycine SDS-polyacrylamide gels. Proteins
were separated alongside a molecular weight marker (BioRad, Hercules, CA,
USA). Protein bands were transferred onto Amersham Hybond-P PVDF
membranes (GE Healthcare, Chalfont, UK). Membranes were blocked with 10%
(w/v) Marvel milk/tris-buffered saline (TBS) solution with 0.05% (v/v) Tween-20
(TBST). Following washes in TBST, membranes were incubated with primary
antibodies (in blocking solution) overnight at 4 1C followed by washing and
incubation with secondary antibodies for 1 h at room temperature, prior to
visualisation using Rapid Step ECL reagent (Calbiochem, Billerica, MA, USA) and
a CCD camera (Fujifilm, Bedford, UK). For IP, the cells were lysed in IP buffer
(0.05 M Tris pH 7.4, 0.15 M NaCl, 0.5% (v/v) Triton X-100, and 0.001 M EDTA).
The extracts were pre-cleared for 1 h at 4 1C using Protein G Plus–Agarose beads
(IP08, Calbiochem) and corresponding IgGs. For the antibody binding, antibodies
to SOCS1, Phospho-Jak1 or Phospho-Tyk2 were incubated with agarose beads
for 2 h in IP buffer before adding the pre-cleared extracts for overnight IP. For
SOCS1 protein labelling, FM82 control cell line was transfected with SOCS1 cDNA
(OriGene, SC111081) and with or without HAGE cDNA . 24 h later the cells were
divided into four flasks, each containing 1 106 cells for each experiment (in the
presence or absence of HAGE). Each flask was incubated in a media without
methionine for 30 min (RPMI-1640, R7513: Sigma) and 50 mM of protein labelling
compound (L-azidohomoalanine) was added (for 0, 30, 60 and 120 min) as
recommended by the manufacturer (Click-it AHA (L-azidohomoalanine) for nascent
protein synthesis, C10102; Invitrogen). The cell extracts from each flask were
treated with Biotin alkyne (Click-it Biotin Protein Analysis Detection Kit, C33372,
Invitrogen) and subjected to IP with SOCS1 antibody, followed by IB with
Streptavidin-HRP.
In vitro transcription and RNA labelling. The plasmid pCMV6-XL4
containing SOCS1 was purchased from OriGene (SC111081) and used for in vitro
transcription using T7 promoter to generate SOCS1 transcript (Ambion, Paisley,
UK). SOCS1 N-terminal RNA complementary sequence 50-ACAACCAGGUGG-
CAGCCGACAAUGCAGUCUCCACAGCAGC-30 labelled using Pierce RNA 30 End
Biotinylation Kit (Thermo Scientific). The labelling efficiency was determined by dot
blotting following the manufacturer’s recommendations.
Native RNA gels and winding/unwinding assay. Biotinylated
N-terminal RNA complementary sequence (2 pmol; labelling efficiency higher that
75%; was placed to wind with unlabelled SOCS1 RNA in a solution containing
3.5 mM equimolar of ATP/MgCl2 for 5 min at 95 1C, followed by 1 h at 37 1C.
Recombinant HAGE protein was added at two different concentrations (0.6mg,
1.2mg) after the RNA winding assay, followed by 1 h incubation at 37 1C. The
reactions were stopped by the addition of 50% (v/v) glycerol, 20 mM EDTA, 2%
(w/v) SDS and 0.025% (w/v) bromophenol blue. Samples were analysed on 10%
(w/v) native acrylamide gels in 1 TBE buffer followed by blot transfer and
visualisation using a Chemiluminescent Detection Module (Thermo Scientific).
Melanoma spheroid cell culture. For the culture of melanoma spheres,
cells from FM82 empty vector, FM82 PMLII, FM82 and FM55 controls and FM82
and FM55 shRNAs were cultured at clonal density (1 104 cells/ml in 24-well
plates) in a DMEM/F12 media (Gibco Invitrogen, Paisley, UK; 32 500)
supplemented with N-2 Max Media (R&D Systems, Minneapolis, MN, USA;
AR009), and daily addition of 100 ng/ml FGF basic and 100 ng/ml EGF (both from
Sigma) for a 10-day culture period.2 The differentiation of melanoma spheres was
induced by the withdrawal of FGF basic and EGF. The cells were stained by IF as
described above. For IFNa studies, the melanoma spheres were cultured for 15
days and IFNa (1000 U/ml) was added at day 9 and 12. Sphere diameters were
measured using Carl Zeiss AxioVision software.
Tumour transplantation assay. NOD/SCID mice were acquired (Harlan
Laboratories, Shardlow, UK) and kept in accordance with the Animals (Scientific
Procedures) Act 1986. The mice were used for tumour transplantation Assay
(xenotransplantation assay) using FM82 control or FM82 shRNA cells, as
previously described.2 When tumours reached 3 mm2 in size (monitored using a
caliper), PBS or IFNa2a (4 106 IU) (PHP107Z, AbD Serotec, Hercules, CA,
USA) were injected locally three times a week for a period of 4 weeks. The
tumours were collected and measured using a rule. The sections were obtained
from three different levels within the tumours (10 sections of 10 mm separating
each level). For determining the tumours cellularity and the counting of the number
of cells expressing the cleaved caspase 3, three pictures were taken randomly
from each sections and from each level and were used for the counting. The
sections were stained by immunohistochemistry/IF as described above.
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